Why McKesson (MCK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why McKesson (MCK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
MCK Stock Gains More Than 4% Following Strong Q4: Should You Buy Now?
McKesson's MCK shares have gained 4.4% following its fourth-quarter fiscal 2025 earnings release on May 9. The post-earnings upside reflects growing investor confidence in McKesson's strategic execution and long-term positioning, underpinned by record full-year revenues of $359 billion and a 20% year-over-year increase in adjusted earnings per share (to $33.05).
McKesson: Sustained Rally Backed By Strong Financials
The stock price of McKesson has maintained a strong upward trend throughout multiple years because of its solid financial performance and dedicated investor support which creates a defensive investment opportunity. The company achieves strong revenue and EPS growth through its expanding oncology, biopharmaceutical and GLP-1 therapy sales, which counterbalance the typical thin margins of the sector. The company's strategic focus on high-growth segments together with its divestment of slow-growth units makes McKesson an attractive long-term investment despite its high valuation and low yield.
McKesson To Spin-Off Its Medical-Surgical Solutions Business
Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a manner that maximizes shareholder value and anticipates providing more information as appropriate on the form and timing as the process progresses.
3 Reasons Growth Investors Will Love McKesson (MCK)
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation (MCK) CFO Britt Vitalone Hosts BofA Securities 2025 Healthcare Conference (Transcript)
McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Allen Lutz Welcome to day one of the BofA Healthcare Conference here in Las Vegas. We are very excited to welcome McKesson here.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson: Spinoff Of Medical-Surgical Solutions Is A Positive, Strong Buy
I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and 63.8% adj. EPS growth, largely driven by strong demand for GLP-1 products, which now represent 12% of total revenue. The company's global supply chain flexibility and non-discretionary drug pricing render it largely immune to tariff uncertainties, ensuring stable future growth.
